The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
Okur is amending its existing shelf registration to continue an at-the-market program for the offer and sale of up to $100,000,000 of Class A common stock through or to Leerink Partners under a Sales Agreement. The company states it is no longer subject to General Instruction I.B.6 of Form S-3, which had limited the amount it could sell under this registration.
As of August 4, 2026, no shares have been offered or sold under this program. The aggregate market value of Class A common stock held by non-affiliates was $167.3 million as of August 3, 2026, based on 36,368,892 non-affiliate shares at $4.60 per share; this is a baseline figure, not the amount being offered. Leerink Partners may receive up to 3.0% of gross proceeds as sales compensation. Okur is characterized as an “emerging growth company” and “smaller reporting company,” and investors are directed to the referenced risk factor sections before investing.
OnKure Therapeutics reported second-quarter 2026 results and progress on its PI3Kα-focused precision medicine pipeline. Lead candidates OKI-355 for vascular anomalies and OKI-345 for breast cancer are in IND-enabling activities, with Investigational New Drug submissions planned for the first half of 2027.
The company highlighted scientific engagement through a Key Opinion Leader event on PI3Kα pan-mutant inhibition and participation at the ISSVA World Congress. As of June 30, 2026, cash, cash equivalents and marketable securities were $176.4 million, expected to fund operations into 2029.
For the quarter, research and development expenses were $12.6 million for both the second quarter of 2026 and 2025, while general and administrative expenses were $4.3 million versus $3.7 million a year earlier. Net loss was $15.3 million, or $0.31 per share, compared with $15.4 million, or $1.14 per share, in the prior-year quarter.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for vascular anomalies and cancers. For the six months ended June 30, 2026, it reported a net loss of $30.5 million, compared with $31.3 million in the prior-year period.
Research and development expenses were $24.3 million and general and administrative expenses were $8.2 million. Cash, cash equivalents and marketable securities totaled $176.4 million, strengthened by a $150.0 million March 2026 private placement of common stock and pre-funded warrants. Management believes this liquidity funds its current operating plan for at least the next 12 months as it prepares IND submissions for OKI-345 and OKI-355 in the first half of 2027.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small automatic share sale tied to equity compensation. He sold 86 shares of Class A Common Stock on June 22, 2026 at a weighted average price of $4.3963 per share to cover tax withholding obligations from vested restricted stock units under the 2023 RSU Equity Incentive Plan. Following this tax-related sale, he holds 11,247 shares directly, including 4,000 shares acquired through the company’s 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics, Inc.’s Chief Financial Officer Jason A. Leverone reported an automatic sale of 303 shares of Class A Common Stock at a weighted average price of $4.3963 per share. The shares were sold to cover tax withholding obligations tied to vesting RSUs. After this transaction, he directly holds 18,802 shares, including 3,105 shares acquired through the 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics director Edward T. Mathers received a stock option grant representing 7,650 shares of Class A Common Stock. The option has an exercise price of $4.30 per share and expires on June 3, 2036. All 7,650 options will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual meeting of stockholders, contingent on his continued service.
OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock. The options have an exercise price of $4.3000 per share and expire on June 3, 2036. According to the vesting terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer's next annual meeting of stockholders, provided he continues as a service provider through the vesting date. Following this grant, he holds 1,275 derivative securities directly in this option award.
OnKure Therapeutics director Andrew John Phillips received a grant of stock options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share. The options vest 100% on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, contingent on his continued service, and expire on June 3, 2036.
OnKure Therapeutics, Inc. director Valerie Malyvanh Jansen received a grant of stock options covering 7,650 shares of Class A Common Stock. The options have an exercise price of $4.30 per share and expire on June 3, 2036.
All 7,650 option shares will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, if she continues as a service provider through that date. Following this grant, she holds 7,650 options directly.
OnKure Therapeutics director Michael G. Grey received a grant of 7,650 stock options to purchase Class A common stock at an exercise price of $4.30 per share. These options vest 100% on the earlier of June 4, 2027 or the day before the company’s next annual stockholder meeting, provided he continues as a service provider, and expire on June 3, 2036.